Welcome to our dedicated page for Alphatec Hldgs SEC filings (Ticker: ATEC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Searching for the most recent Alphatec Holdings insider trading Form 4 transactions or trying to decode an FDA comment buried deep in a 10-K? Investors often start with a single question—yet end up juggling hundreds of pages about spinal-implant clearances, surgeon partnerships, and R&D milestones. Our SEC filings hub puts every document in context, so you can focus on the implications for spinal-surgery innovation rather than on document hunting.
Each new Alphatec Holdings quarterly earnings report 10-Q filing arrives on Stock Titan within seconds of hitting EDGAR. AI then produces a concise Alphatec Holdings earnings report filing analysis, flags segment revenue shifts, and links directly to tables that matter to spine-device margins. Prefer real-time governance data? Alphatec Holdings Form 4 insider transactions real-time alerts track when surgeon-directors buy or sell shares—perfect for spotting confidence signals before product launches.
Need a high-level view? Start with Alphatec Holdings annual report 10-K simplified summaries that unpack R&D spend, FDA pathways, and competitive positioning. For event-driven traders, Alphatec Holdings 8-K material events explained highlights new product approvals and litigation updates within minutes. If compensation trends guide your valuation models, the Alphatec Holdings proxy statement executive compensation section is mapped to historical pay metrics. And if you just want the facts, "understanding Alphatec Holdings SEC documents with AI" quickly answers natural-language queries like “How much did R&D grow?” while “Alphatec Holdings SEC filings explained simply” gives plain-English context.
From compliance alerts to in-depth analysis, our platform turns Alphatec Holdings executive stock transactions Form 4 data and every other filing type into actionable spinal-tech insight—so you spend your time on decisions, not document searches.
ANSYS Inc. (ANSS) Form 4 highlights insider activity by President & CEO Ajei Gopal on 07/11/2025.
Gopal exercised 92,018 stock options (Code M) at an exercise price of $95.09 per share. The options originated from a 08/31/2016 grant that vested in 25% annual tranches and were due to expire on 08/31/2026.
To satisfy tax obligations arising from the exercise, 50,379 shares were automatically withheld (Code F) at a market price of $374.52. No open-market sale was reported.
After these transactions, the CEO’s direct beneficial ownership stands at 398,931 common shares, which includes 27,284 Deferred Stock Units and 152,530 Restricted Stock Units. All derivative securities from the 2016 option grant have now been settled, leaving 0 options outstanding from this award.
The net effect is an increase of 41,639 shares in the CEO’s direct holdings, signalling continued alignment with shareholder interests through a larger equity stake.
ANSYS Inc. (ANSS) Form 4 highlights insider activity by President & CEO Ajei Gopal on 07/11/2025.
Gopal exercised 92,018 stock options (Code M) at an exercise price of $95.09 per share. The options originated from a 08/31/2016 grant that vested in 25% annual tranches and were due to expire on 08/31/2026.
To satisfy tax obligations arising from the exercise, 50,379 shares were automatically withheld (Code F) at a market price of $374.52. No open-market sale was reported.
After these transactions, the CEO’s direct beneficial ownership stands at 398,931 common shares, which includes 27,284 Deferred Stock Units and 152,530 Restricted Stock Units. All derivative securities from the 2016 option grant have now been settled, leaving 0 options outstanding from this award.
The net effect is an increase of 41,639 shares in the CEO’s direct holdings, signalling continued alignment with shareholder interests through a larger equity stake.
Hyatt Hotels Corporation (NYSE: H) filed a Form 144 indicating a proposed sale of up to 4,078 common shares acquired as restricted stock units on 03/16/2025. The shares, representing less than 0.01% of the 41.94 million shares outstanding, have an aggregate market value of roughly $600,000. The planned transaction will be executed through Morgan Stanley Smith Barney LLC on or about 07/10/2025. No other sales have been reported by the filer in the past three months. Given the small size relative to Hyatt’s public float, the filing is routine and should have minimal impact on shareholder dilution or trading liquidity.
Hyatt Hotels Corporation (NYSE: H) filed a Form 144 indicating a proposed sale of up to 4,078 common shares acquired as restricted stock units on 03/16/2025. The shares, representing less than 0.01% of the 41.94 million shares outstanding, have an aggregate market value of roughly $600,000. The planned transaction will be executed through Morgan Stanley Smith Barney LLC on or about 07/10/2025. No other sales have been reported by the filer in the past three months. Given the small size relative to Hyatt’s public float, the filing is routine and should have minimal impact on shareholder dilution or trading liquidity.
FAQ
What is the current stock price of Alphatec Hldgs (ATEC)?
What is the market cap of Alphatec Hldgs (ATEC)?
What is the primary focus of Alphatec Holdings Inc?
How does Alphatec enhance the surgical treatment of spinal disorders?
Which surgical procedures are addressed by Alphatec's product platforms?
How does Alphatec generate value in the competitive medtech industry?
What distinguishes Alphatec’s business model from other companies in the field?
In what ways does Alphatec maintain its market relevance?
Does Alphatec engage in direct partnerships with clinical experts?
How does Alphatec contribute to improved patient outcomes?
